Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tg Therapeutics (TGTX) FCF Margin (2016 - 2025)

Tg Therapeutics (TGTX) has 10 years of FCF Margin data on record, last reported at 10.17% in Q4 2025.

  • For Q4 2025, FCF Margin rose 3389.0% year-over-year to 10.17%; the TTM value through Dec 2025 reached 4.05%, up 827.0%, while the annual FY2025 figure was 4.05%, 827.0% up from the prior year.
  • FCF Margin reached 10.17% in Q4 2025 per TGTX's latest filing, up from 14.37% in the prior quarter.
  • Across five years, FCF Margin topped out at 50.48% in Q3 2023 and bottomed at 36701.06% in Q3 2022.
  • Average FCF Margin over 5 years is 5026.45%, with a median of 145.68% recorded in 2023.
  • Peak YoY movement for FCF Margin: skyrocketed 15337188bps in 2021, then plummeted -3338678bps in 2022.
  • A 5-year view of FCF Margin shows it stood at 3747.91% in 2021, then plummeted by -696bps to 29841.25% in 2022, then soared by 100bps to 30.04% in 2023, then grew by 21bps to 23.72% in 2024, then skyrocketed by 143bps to 10.17% in 2025.
  • Per Business Quant database, its latest 3 readings for FCF Margin were 10.17% in Q4 2025, 14.37% in Q3 2025, and 5.24% in Q2 2025.